Neprilysin functional genetic polymorphism in NSCLC progression without PD-L1 expression Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020
Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer> Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021
Tumor specific MUC1 expression in operable lung cancer correlates with improved survival Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005
Loss of orphan G protein coupled receptor GPRC5A is associated with metastatic disease and poor survival in patients with adenocarcinomas of the lung Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011
The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
Clinical evaluation of the plasma levels of hTERT and EGFR expression as markers for early detection of non-small cell lung cancer Source: Annual Congress 2009 - Basic science and lung cancer Year: 2009
Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020
Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients Source: Eur Respir J 2006; 28: Suppl. 50, 810s Year: 2006
Gene expression profiling in non-small cell lung cancer (NSCLC) according to smoking status Source: Annual Congress 2008 - Discovery of novel targets in lung disease by means of functional genomics Year: 2008
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009
E-cadherin and beta-catenin expression in imprints of NSCLC. Relationship with prognostic parameters Source: Eur Respir J 2006; 28: Suppl. 50, 769s Year: 2006
Positive PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with EGFR-TKIs Source: International Congress 2019 – Treatment of lung cancer Year: 2019
Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020
Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
Immunohistochemical expression of Bcl-2 and p53 in patients with lung cancer: Correlation with survival time Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012
Collagen1a1 mRNA expression in BAL cells is associated with disease progression and poor survival in ILDs Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis Year: 2020